Senzer Plans to Launch Its Inhaled Cannabinoid Products in the UK …

LONDON, July 5, 2018 /CNW/ – Senzer Ltd has announced that it intends to launch its inhaled cannabinoid portfolio of products later this year in the UK under a specials pharmaceutical licence. This would enable doctors to prescribe its inhaled cannabinoid products to cancer patients undergoing chemotherapy.

“Our delivery technology is a first of its kind – a respiratory delivery system that uses a breath-operated valve technology and delivers pharmaceutical grade cannabinoids rapidly into the bloodstream,” Senzer CEO Alex Hearn has said.

With over 300,000 people across Europe and the US currently experiencing the most common side effects more at